Corporate Presentation April 2016

ASH 2015 Investor and Analyst Event

ASH 2014 Investor and Analyst Event


2015 Annual Report
Download here


Asterias Stock Tax Guidance
Download here

Corporate Profile
Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Recent NewsMore >>
07/13/16Geron Announces Issuance of U.S. Patents Related to ImetelstatPrinter Friendly Version
05/05/16Geron Corporation Reports First Quarter 2016 Financial Results and Recent EventsPrinter Friendly Version
04/27/16Geron Announces Conference Call to Discuss First Quarter 2016 Financial ResultsPrinter Friendly Version
Upcoming EventsMore >>
To be announced.
Stock Information
GERN (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Down 0.04 (1.48%)
Data as of 07/22/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Contact Information

Anna Krassowska, Ph.D.
Tel: 650-473-7700
E-mail: or

RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | Financial Tear Sheet Financial Tear Sheet
Form content here please :)